Skip to content

US · BLSM · BIOTECHNOLOGY

BlossomHill Therapeutics, Inc. (BLSM) intrinsic value and stock valuation

$25.74as of 2026-09-18 · Mkt cap 763.38M

Data updated · price as of 2026-09-18

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BlossomHill Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values BLSM with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from BLSM’s statements →

BlossomHill Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA, US bhtherapeutics.com

How the business is doing

Fiscal 2025–2024, USD

Revenue
$0.00
20252024
Net income
-$-30.7T
20252024
Free cash flow
-$-31.51T
20252024
Total equity
-$-72.88T
20252024

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2024, USD
FYFY
Revenue$0.00$0.00
Operating income-$-64.02T-$-36.4T
Net income-$-60.56T-$-30.7T
EPSd-$-2.08M-$-1.06M
Operating cash flow-$-46.93T-$-31.42T
Capital expenditure-$-1.07T-$-92B
Free cash flow-$-47.99T-$-31.51T
Total assets$163T$106.8T
Total debt$22.4T$525B
Net debt-$-114.28T-$-99.62T
Total equity-$-131.73T-$-72.88T
Cash and short-term investments$136.7T$100.1T
Income statement
FYFY
Revenue$0.00$0.00
Cost of revenue$0.00$0.00
Gross profit$0.00$0.00
Research and development expenses$56.1T$31.8T
Selling, general and administrative expenses$7.89T$4.59T
Other expenses$0.00$0.00
Operating expenses$64T$36.4T
Cost and expenses$64T$36.4T
Interest income$3.48T$5.71T
Interest expense$0.00$0.00
Depreciation and amortization$441B$350B
Ebitda-$-63.58T-$-36.05T
Operating income-$-64.02T-$-36.4T
Total other income/expenses, net$3.47T$5.71T
Income before tax-$-60.56T-$-30.7T
Income tax expense$0.00$0.00
Net income-$-60.56T-$-30.7T
Weighted average shares outstanding$29.1T$29.1T
Weighted average diluted shares outstanding$29.1T$29.1T
Balance sheet
FYFY
Cash and short-term investments$136.7T$100.1T
Net receivables$0.00$0.00
Inventory$0.00$0.00
Total current assets$138.8T$104.2T
Property, plant and equipment, net$21.6T$1.5T
Goodwill and intangible assets$89B$89B
Long-term investments$0.00$0.00
Total non-current assets$24.1T$2.6T
Total assets$163T$106.8T
Accounts payable$2.31T$849B
Short-term debt$5B$525B
Deferred revenue$0.00$0.00
Total current liabilities$15.5T$6.77T
Long-term debt$22.4T$0.00
Deferred revenue, non-current$0.00$0.00
Total non-current liabilities$279.2T$172.9T
Capital lease obligations$22.4T$525B
Total liabilities$294.7T$179.7T
Common stock$1B$1B
Retained earnings-$-135.03T-$-74.47T
Accumulated other comprehensive income (loss)$0.00$0.00
Total equity-$-131.73T-$-72.88T
Total investments$0.00$0.00
Total debt$22.4T$525B
Net debt-$-114.28T-$-99.62T
Cash flow statement
FYFY
Net income-$-60.56T-$-30.7T
Depreciation and amortization$441B$350B
Stock-based compensation$1.09T$504B
Change in working capital$10.8T-$-2.27T
Accounts receivable$0.00$0.00
Inventory$0.00$0.00
Accounts payable$1.47T-$-1.14T
Net cash provided by operating activities-$-46.93T-$-31.42T
Investments in property, plant and equipment-$-1.07T-$-92B
Acquisitions, net$0.00$0.00
Net cash used for investing activities-$-1.07T-$-92B
Common stock issued$0.00$0.00
Common stock repurchased$0.00$0.00
Dividends paid$0.00$0.00
Net cash used for financing activities$84.5T$17.6T
Net change in cash$36.5T-$-13.95T
Cash at end of period$136.7T$100.1T
Operating cash flow-$-46.93T-$-31.42T
Capital expenditure-$-1.07T-$-92B
Free cash flow-$-47.99T-$-31.51T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BlossomHill Therapeutics, Inc.

        Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

        CEO
        Jing Rong Jean Cui
        Employees
        63
        Beta
        0.00

        Explore

        Frequently asked questions

        What is the intrinsic value of BlossomHill Therapeutics, Inc. (BLSM)?

        BlossomHill Therapeutics, Inc. (BLSM) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BLSM undervalued?

        BLSM trades at a price of $25.74 (Sep 19, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.